Portfolio Careers

Discover opportunities across our network of transformational companies
Amplitude Ventures
Amplitude Ventures
14
companies
19
Jobs
Powered by Getro
Showing 14 companies
Biotechnology
DeepTech
Finance
Health
Sustainability
11 - 50
Series B
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeutic and commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030. It was launched by adMare BioInnovations, Canada’s global life sciences venture, in partnership with industry leaders AbCellera, and some of the country’s most successful scientist entrepreneurs.
Finance
Health
11 - 50
Amplitude Venture Capital deploys a growth model that has successfully been used to build Canadian companies with world-class management teams and scale companies to breakout potential. Since 2012 Amplitude's founding team has raised over $700 million of equity capital in private and public markets. Amplitude, with offices in Montreal, Toronto, and Vancouver, launched its first private capital fund in November 2019, a $200-million fund that applies a proven, evidence-based approach to investing in leading Canadian precision medicine companies.
Biotechnology
DeepTech
Health
51 - 200
Series B
Celsius Therapeutics develop life-changing medicines and discover critical biomarkers for patient care by better understanding the cellular ecosystem of diseases through Single Cell Genomics and Machine Learning.
Biotechnology
DeepTech
Health
11 - 50
Series A
Congruence Therapeutics operates as a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding.
Biotechnology
DeepTech
Health
Software
51 - 200
Series C+
Deep Genomics recruits from among the top 1% of recent graduates and seasoned experts at the intersection of genomics, drug development and AI.
DeepTech
Health
Software
Transportation
51 - 200
Seed
DrugBank augments human intelligence to improve the world’s health. We offer a suite of products that enable companies to improve healthcare delivery through precision medicine or clinical software application and uncover insights through data science in drug discovery. Our publicly accessible resource, DrugBank Online, has been cited in over 13,000 academic publications and is used by millions of researchers and health professionals globally.
Biotechnology
DeepTech
11 - 50
Series B
Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines for inflammatory diseases.
Biotechnology
DeepTech
Health
Software
11 - 50
Series A
Gandeeva Therapeutics has developed a proprietary platform that combines innovative technologies across biochemistry, structural biology, imaging and machine learning to characterize protein-drug interactions at the atomic level, all designed to provide new insights into targeting protein function.
Biotechnology
DeepTech
Health
Software
Series A
The notch develops immune cell therapy developing a next-generation pipeline that is compatible and focuses on initial cancer cells.
Biotechnology
DeepTech
Health
11 - 50
Series B
Prilenia is a provider of biotechnology services. Improving the lives of patients and their families, by developing treatments for neurodegenerative and neurodevelopmental disorders, lies at the heart of Prilenia’s mission.
Biotechnology
DeepTech
Health
51 - 200
IPO
Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells. The company's drugs combine a proprietary high throughput gene-editing and target discovery method with high-resolution protein crystallography, computational biology and clinical informatics, enabling patients to improve cancer treatment both with single therapy and in combination with existing drugs and treatments.
Biotechnology
DeepTech
Finance
Health
11 - 50
Thryv Therapeutics Inc., previously called LQT Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. They have been pioneering a precision medicine approach to treat Long QT Syndrome via SGK1 inhibition since 2019 and have since evolved their portfolio to include the treatment of resistant and rare cancers. The development of SGK1 inhibitors represents a novel approach to target treatment-resistant cancers, and complement existing therapies. This strategic evolution has secured an additional US$15M financing fuelling Thryv to complete a proof-of-concept study for LQTS, and submit an IND for the treatment of resistant cancer. Thérapeutiques Thryv Inc, précédemment appelée Thérapeutiques QTL Inc, est une entreprise privée basée à Montréal, Québec, Canada. Depuis 2019, ils sont les pionniers d'une approche de médecine de précision pour traiter le syndrome du QT long via l'inhibition de SGK-1 et ont depuis évoluer pour inclure le traitement des cancers résistants et rares. Le développement des inhibiteurs de SGK-1 représente une nouvelle approche pour cibler les cancers résistants aux traitements, et compléter les thérapies existantes. Cette évolution stratégique a permis d'obtenir un financement supplémentaire de 15 millions de dollars US qui alimentera Thryv pour compléter une étude de preuve de concept pour le LQTS, et soumettre une IND pour le traitement des cancers résistantes.